The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2008, 181, 3099 -3107
Copyright © 2008 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumura, S.
Right arrow Articles by Demaria, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumura, S.
Right arrow Articles by Demaria, S.

Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1

Satoko Matsumura*, Baomei Wang2,*, Noriko Kawashima*, Steve Braunstein{dagger}, Michelle Badura{dagger}, Thomas O. Cameron*, James S. Babb{ddagger}, Robert J. Schneider{dagger}, Silvia C. Formenti§, Michael L. Dustin* and Sandra Demaria3,*

* Department of Pathology, {dagger} Department of Microbiology, {ddagger} Department of Radiology, and § Department of Radiation Oncology, New York University School of Medicine, New York, and Program in Molecular Pathogenesis, Helen L. and Martin S. Kimmel Center for Biology and Medicine, Skirball Institute for Biomolecular Medicine, New York, NY 10016

Recruitment of effector T cells to inflamed peripheral tissues is regulated by chemokines and their receptors, but the factors regulating recruitment to tumors remain largely undefined. Ionizing radiation (IR) therapy is a common treatment modality for breast and other cancers. Used as a cytocidal agent for proliferating cancer cells, IR in combination with immunotherapy has been shown to promote immune-mediated tumor destruction in preclinical studies. In this study we demonstrate that IR markedly enhanced the secretion by mouse and human breast cancer cells of CXCL16, a chemokine that binds to CXCR6 on Th1 and activated CD8 effector T cells, and plays an important role in their recruitment to sites of inflammation. Using a poorly immunogenic mouse model of breast cancer, we found that irradiation increased the migration of CD8+CXCR6+ activated T cells to tumors in vitro and in vivo. CXCR6-deficient mice showed reduced infiltration of tumors by activated CD8 T cells and impaired tumor regression following treatment with local IR to the tumor and Abs blocking the negative regulator of T cell activation, CTLA-4. These results provide the first evidence that IR can induce the secretion by cancer cells of proinflammatory chemotactic factors that recruit antitumor effector T cells. The ability of IR to convert tumors into "inflamed" peripheral tissues could be exploited to overcome obstacles at the effector phase of the antitumor immune response and improve the therapeutic efficacy of immunotherapy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grant R01 CA113851, Research Scholar Award RSG-05-145-01-LIB from the American Cancer Society, and a grant from The Chemotherapy Foundation, (to S.D.). Additional support was provided by National Institutes of Health Grant R01AI55037 (to M.L.D.) and a Cancer Research Institute postdoctoral fellowship (to T.O.C.). The New York University Cancer Institute is supported by National Institutes of Health Grant 5P30 CA016087-27.

2 Current address: Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8118, St. Louis, MO 63110.

3 Address correspondence and reprint requests to Dr. Sandra Demaria, Department of Pathology, Medical Science Building, Room 504, New York University School of Medicine, 550 First Avenue, New York, NY 10016. E-mail address: demars01{at}med.nyu.edu

4 Abbreviations used in this paper: IT, immunotherapy; HA, hemagglutinin; IR, ionizing radiation; MPase, metalloproteinase; NS, nonsilencing; sh, short hairpin; Tc1, T cytotoxic 1; TDLN, tumor-draining lymph node; TIL, tumor infiltrating lymphocyte; WT, wild type.




This article has been cited by other articles:


Home page
Sci Transl MedHome page
J. B. Maxhimer, D. R. Soto-Pantoja, L. A. Ridnour, H. B. Shih, W. G. DeGraff, M. Tsokos, D. A. Wink, J. S. Isenberg, and D. D. Roberts
Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling
Science Translational Medicine, October 21, 2009; 1(3): 3ra7 - 3ra7.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Z. Dewan, A. E. Galloway, N. Kawashima, J. K. Dewyngaert, J. S. Babb, S. C. Formenti, and S. Demaria
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
Clin. Cancer Res., September 1, 2009; 15(17): 5379 - 5388.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. A. Pilones, N. Kawashima, A. M. Yang, J. S. Babb, S. C. Formenti, and S. Demaria
Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade
Clin. Cancer Res., January 15, 2009; 15(2): 597 - 606.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.